Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin - subcutaneous implant - 3.6 mg - active: leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin excipient: polyglactin - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg - subcutaneous implant - 5 mg - active: leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg excipient: poly(lactide) - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma

Australia - inglese - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - water for injections, quantity: 4.2 ml - injection - excipient ingredients: - firmagon is a gnrh receptor blocker indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - water for injections, quantity: 3 ml - injection - excipient ingredients: - firmagon is a gnrh receptor blocker indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted.

Malta - inglese - Malta Medicines Authority

aa-pharma ul. sapiezynska 10, 00-215 warsawa, poland - goserelin acetate - implant - goserelin acetate 3.6 gram(s) - endocrine therapy

Malta - inglese - Malta Medicines Authority

aa-pharma ul. sapiezynska 10, 00-215 warsawa, poland - goserelin acetate - implant - goserelin acetate 10.8 gram(s) - endocrine therapy

Malta - inglese - Malta Medicines Authority

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - leuprorelin acetate - implant - leuprorelin acetate 5 mg - endocrine therapy

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nafarelin, quantity: 2 mg/ml - spray, solution - excipient ingredients: benzalkonium chloride; sorbitol; glacial acetic acid; hydrochloric acid; purified water; sodium hydroxide - indications as at 31 august 1995. synarel is indicated for the hormonal management of visually proven endometriosis, including pain relief and reduction of endometriotic lesions and for use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist.

Israele - inglese - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Israele - inglese - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.